Cytokinetics (CYTK)

Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.

Dagens Cytokinetics, Incorporated Common Stock (CYTK) aktiekurs på är , vilket speglar en NaN % rörelse sedan marknaden öppnade. Företagets marknadsvärde är 7,46 md $, med en daglig handelsvolym på  aktier. Det tidigare stängningspriset var .

Redo att börja? Följ stegen nedan, eller läs vår guide om hur man köper Cytokinetics aktier på Kraken med start från 10 $.